|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's Range||26.29 - 26.49|
|52 Week Range||24.80 - 39.19|
|Beta (5Y Monthly)||0.40|
|PE Ratio (TTM)||23.32|
|Forward Dividend & Yield||0.75 (2.88%)|
|Ex-Dividend Date||Mar 31, 2022|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for SNN
Oh dear. Just when it seemed like Smith & Nephew was making progress, the FTSE 100 company has dished out another profits warning.
In this article we are going to estimate the intrinsic value of Smith & Nephew plc ( LON:SN. ) by taking the forecast...
Smith & Nephew Plc (NYSE: SNN) reported Q2 revenue of $1.29 billion, up 1.2% on an underlying basis but down 3.1% on a reported basis, including a 430 basis point foreign exchange headwind. Orthopedics revenue declined 1.1%, or by 4.9% on a reported basis, reflecting execution and supply chain challenges. Sports Medicine and ENT were up 1.9%, but down 2.4% on a reported basis, with growth “significantly impacted” by the Covid-related lockdown in China. Advanced wound management grew 3.8% but fel